EyePoint is a clinical-stage biopharmaceutical company developing treatments for retinal diseases, with its entire focus on a single lead asset: DURAVYU, currently in Phase 3 trials for wet AMD and DME. DURAVYU combines vorolanib, a small-molecule tyrosine kinase inhibitor (TKI) that blocks VEGF receptors, with EyePoint's proprietary Durasert E bioerodible sustained-release insert, delivered via a standard in-office intravitreal injection. The core value proposition is extending the treatment interval for wet AMD and DME patients to six months, versus the one-to-three-month injection schedule required by existing anti-VEGF biologics. EyePoint also argues vorolanib offers a differentiated mechanism — blocking VEGF at the receptor level intracellularly, inhibiting PDGF (potentially antifibrotic), and inhibiting IL-6/JAK1 inflammatory signaling — versus approved ligand-blocking antibodies. Phase 3 enrollment is complete for both wet AMD trials (LUGANO and LUCIA, over 900 patients combined), with top-line data expected in mid-2026. DME Phase 3 trials (COMO and CAPRI) dosed their first patient in early 2026, with data expected in 2027. EyePoint has no commercial revenue and is burning cash to advance DURAVYU through trials. If approved, EyePoint plans to commercialize DURAVYU independently in the U.S., targeting retinal specialists directly, and has already built out manufacturing capacity in Northbridge, MA. Outside the U.S., EyePoint has licensed Greater China rights to Betta Pharmaceuticals. EyePoint held $306M in cash at year-end 2025, which management expects to fund operations into 2027.